




CAPE TOWN - A CLINICAL AND
HISTOPATHOLOGICAL STUDY
E R Lemmer, J E J Krige, P de la M Hall, P C Bornman,
D A Taylor, JTerblanche
Objective. Review of surgical resections performed for
hepatocellular carcinoma (BCC) at our institution between
1990 and 1996, histology of resected specimens, and clinical
outcome.
patient survival at 1, 2 and 3 years was 85%, 75%, and 62%,
respectively. Histopathology of the resected specimens
showed that 10 of 14 tumours had arisen in non-cirrhotic
livers. Mean tumour size was 10.6 (4.6) cm. Only 1 specimen
showed the fibrolamellar variant of HCC.
Conclusions. Only a small proportion of patients with HCC
seen at Groote Schuur Hospital were eligible for resection,
and only a minority of these had HBV-associated 'African'
HCC. The results of hepatic resection at our institution
compare favourably with literature reports, despite the
relatively large size of the tumours. It is of interest that most
tumours arose in non-cirrhotic livers. There was no evidence
of proliferation of 'oval-like' cells in non-neoplastic liver
tissue.
Design, Retrospective and prospective study of 14 patients
who underwent resection for HCC.
Setting. The Hepatobiliary Unit and Liver Clinic, Groote
Schuur Hospital, Cape Town.
Patients. Fourteen patients who underwent liver resections for
HCC.
Interventions. Hepatic resections using prolonged vascular
inflow occlusion.
Outcome measures. Clinical outcome and disease-free survival
following resection.
Results. Fourteen patients (5.6% of the total number
presenting with HCC) underwent liver resection for HCC at
our institution between 1990 and 1996. There were 7 men,
median age 40 years (range 18 - 74 years). Only 2 patients
were black, and only 1 of these patients had evidence of
hepatitis B virus (HBY) infection in the liver. Extensive liver
resections were often required. The mean (SD) ischaemic time
was 81 (26) minutes and mean estimated blood loss was 938
(649) ml. During hospital admission, 1 patient developed a
minor bile leak that settled spontaneously, and 1 patient
suffered a stroke and died. The mean hospital stay following
operation was 12 days (range 7 - 21 days). Disease-free
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The treatment of patients with hepatocellular carcinoma (HCC)
is influenced by the clinical stage of the disease, presence or
absence of cirrhosis, and degree of liver impairment.1.2 Surgery
is the primary option for all patients without cirrhosis, and for
many cirrhotics who have a single tumour less than 5 cm in
diameter with well-preserved hepatic function.',2 Resection is
the treatment of choice for patients with HCC arising in non-
cirrhotic livers. In three studies the 5-year survival of 196 non-
cirrhotic patients with HCC treated with hepatic resection was
43%.3-5 Hepatic resection and liver transplantation offered the
best chances of cure in cirrhotic patients with a single tumour,
with a 50% reported 5-year survival.'.'·· The best long-term
survivals were in patients with incidental tumours in the
implanted liver. Their outcome was no different from that of
patients transplanted for cirrhosis alone.'"
Orthotopic liver transplantation (OLT) has the potential to
cure both the tumour and cirrhosis, which is the most frequent
site of occult satellite nodules, and is premalignant.7~ Patients
with more advanced tumours are rarely eligible for surgery
and have a dismal prognosis. For those with small tumours
whc are not eligible for surgery, percutaneous ethanol injection
appears to be an effective and affordable treatment modality...n
Randornised trials of targeted chemotherapy" and chemo-
embolisation13_14 have not shown any survival benefit, and have
caused significant treatment-related morbidity.
In Western countries with a low incidence of HCC, the
tumour usually complicates longstanding symptomatic
cirrhosis in elderly patients, and the cause is usually alcoholic
in origin." However, in sub-Saharan Africa, where the
incidence of HCC is very high, tumours frequently arise in
young patients who do not have cirrhosis, and the commonest
predisposing condition is chronic hepatitis B virus (HBY)
infection'··l7 Both forms of HCC are seen in South Africa
because of the ethnic diversity of the population.
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Table I. Surgical resections for HCC - patient details
RESULTS
Outcome measures
Operative mortality was defined as intra-operative death or
death within 2 months of the operation. Operative mortality
was not excluded from the survival curves. Total survival and
disease-free survival were analysed according to the Kaplan-














were selected from the tumours and surrounding non-
neoplastic liver tissue. Formalin-fixed tissue was routinely
processed and embedded in paraffin. Sections were cut at 5 p.m
for haematoxylin and eosin (H&E) and immunohistochemical
staining. Immunohistochemical staining was performed using
the following antibodies: rabbit polyclonal antibody to human
AFP (DAKO, Copenhagen, Denmark); antibody against HBsAg
(BioGenex, San Ramon, Calif.); monoclonal antibody to
cytokeratin 19 (CK 19; Boehringer-Mannheim, Indianapolis,
Ind.); monoclonal antibody to rat oval cells (OV-6; a generous
gift from Dr S Sell, Albany, fY); antibody to endothelial cells
(CD 34; Becton-Dickinson, Lincoln Park, NJ); and polyclonal
carcino-embryonic antigen (CEA) stain to outline canaliculi
(Poly CEA; DAKO, Copenhagen, Denmark).
Fourteen of 248 patients with HCC seen at Groote Schuur
Hospital between January 1990 and February 1996 underwent
liver resection for cure. Patient characteristics are shown in
Table I. There were 7 male patients, median age 40 years (range
18 - 74 years). The proportion of patients undergoing resection
according to ethnic group was as follows: 7 of 34 were white
(20.6%),5 of 95 were coloured (5.3%), and 2 of 119 were black
(1.7%). Only 1 of the 2 black patients showed evidence of HBV
infection. Serum HBsAg was present in 3 of 8 patients tested,
and serum AFP was raised in 5 of 8 patients. Resections
performed were left hepatectomy (6 patients), right
hepatectomy (4 patients), extended right hepatectomy (3
patients), and segment IV resection (1 patient). The mean (SD)
ischaemic time was 81 (26) minutes and mean estimated blood
loss was 938 (649) ml. Only 5 patients required a blood
transfusion, and the mean volume transfused was 1 050
(542) ml. During hospital admission 1 patient developed a
minor bile leak that settled spontaneously, and 1 patient
suffered a stroke and died. The mean hospital stay following
The aim of this study was to review the results of surgical
resection for HCC at Groote Schuur Hospital and to examine
the histopathology of the resected specimens.
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PATIENTS AND METHODS
Between January 1990 and February 1996 14 patients with HCC
underwent surgical curative resection at Groote Schuur
Hospital in Cape Town. During. this period, a total of 248 HCC
patients were seen at our institution. Selection criteria for .
hepatic resection included: tumour confined to either lobe of
the liver, absence of vascular invasion or extrahepatic spread of
tumour, good hepatic reserve, and absence of other significant
medical illness. Pre-operative evaluation included full clinical,
haematological, biochemical and radiographic assessment to
confirm the diagnosis and to facilitate surgical planning. All
potential candidates for resection had selective hepatic
arteriography and CT portography in order to exclude vascular
invasion and to obtain a precise knowledge of hepatic vascular
anatomy." Results of serum hepatitis B surface antigen
(HBsAg) and serum a-fetoprotein (AFP) levels were available
for 8 of 14 patients. Pre-operative biopsy to prove the nature of
the liver mass or to assess the status of the surrounding liver
was not performed. In 1 patient pre-operative selective hepatic
artery embolisation of the tumour was performed to reduce
tumour size and improve resectability by producing
hypertrophy of the opposite lobe.
The individual liver resections were planned according to the
site of the tumour and the lobar or segmental anatomy of the
liver.'9,2ll Intra-operative ultrasound was used to exclude
additional tumours, and to determine the hepatic vascular
anatomy in relation to the tumour. Hepatic resection was
performed with the use of the Pringle manoeuvre with
intermittent vascular inflow occlusion to reduce blood loss and
blood transfusion requirements!' Complete haemostasis and
control of bile leakage were important intra-operative
considerations to prevent postoperative complications. The
liver parenchyma was divided by a clamp fracture technique.
Larger blood vessels and all bile ducts were sutured prior to
ligation and division. Electrocautery was used for small vessels
at the divided edge of the parenchyma. '9,2ll Fibrin sealant
(T1sseallmmuno, Osterreichisches Institut fur Haemoderivate,
Vienna, Austria) was sprayed on the raw surface area of the
resected liver, and abdominal drainage was not routinely
performed.2l All patients were ventilated in the intensive care
unit for the first 24 hours. After discharge, patients were
monitored for recurrent HCC by means of clinical examination,
liver profile tests, ultrasound, AFP assay and chest radiography
at 6-monthly intervals.
Pathology
On receipt of the resected liver tumours, the largest tumour
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Fig: 1. Kaplan-Meier suroival analysis ofdisease-free suroival of
patlents followmg resection for HCC.
operation was 12 days (range 7 - 21 days). After a median
follow-up period of 32 months (range 6 - 68 months) 8 of 13
patients were alive and disease-free, 1 patient was alive with
recurrent tumour, and 4 patients had died from recurrent HCC.
Tumour recurrence was intrahepatic in all 5 patients, and in
addition 1 patient developed pulmonary metastases. The
disease-free patient survival at 1, 2 and 3 years was 85%, 75%,
and 62% respectively (Fig. 1).
Gross pathological examination of the resected specimens
revealed a mean tumour diameter of 10.6 (4.6) cm.
Histopathology showed that 10 tumours had arisen in non-
cirrhotic livers (Fig. 2, a), and only 4 tumours complicated
cirrhosis. H&E staining revealed that 13 tumours had a
trabecular pattern, and only one fibrolamellar variant of HCC
was found. Immunohistochemical staining showed turnour
AFP positivity in 5 cases (Fig. 2, b) and HBsAg positivity of
surrounding liver in 1 case. Staining with CD34 demonstrated
the highly vascular nature of the tumours (Fig, 2, c), but did
not stain sinusoids in the adjacent liver. Polyclonal CEA
staining of the tumours outlined the canalicular network
(Fig. 2, d).
The surrounding non-neoplastic liver tissue was examined
for the presence of bile ductular and/or stem ('oval-like') cell
proliferation. Immunostaining with CK19 and OV-6 showed
'reactive' bile ductular proliferation in the fibrous tissue at the
edge of the tumours in cirrhotic livers and some non-eirrhotic
livers (Fig. 2, e, f), with no evidence of proliferation of 'oval-
like' stern cells in any of the livers examined.
DISCUSSION
Less than 5% of patients seen with HCC at our institution were
treated by surgical resection. On average, only two resections
per year were performed for HCC in this tertiary referral
centre. Furthermore most resections were clearly not performed
for'African' HBV-related HCC. Of salient interest in this small
series was the observation that the majority of tumours were in
non-cirrhotic livers. This is almost certainly due to selection
bias, younger patients with good liver function being selected
for surgery. The underlying cause(s) of HCC in these patients is
not clear. The relationship between HCC and cirrhosis in
southern African blacks differs substantially from that in low-
incidence regions of the tumour, while in some areas the
incidence of HCC may exceed that of cirrhosis." In a study of
southern African blacks with HCC, Kew17 found that 37% of
patients did not have cirrhosis. He found no differences in the
age (mean 35 years), clinical features, hepatic function, serum
AFP concentrations, or HEV status between HCC patients with
cirrhosis and those without. However, as mentioned before,
this surgical series is not representative of HBV-associated
'African' HCC. Although most of these patients present late in
the course of their disease when surgical cure is not possible,
there is evidence that HCC in Africa follows a more aggressive
course than HCC in the Orient, and even small tumours are
unencapsulated. I"
The technique of hepatic resection for malignant tumours has
been greatly simplified by the use of prolonged intermittent
vascular inflow occlusion",23 and intra-operative ultrasound.
Resections, which were often extensive, were well tolerated, as
evidenced by the low transfusion requirement and short
hospital stay of the patients. There was 1 hospital death from
an unrelated cause (stroke), and 1 patient developed a minor
bile leak that settled spontaneously. The long-term outcome of
our patients compares favourably with that reported from
larger surgical series.3•24.25 This is encouraging, particularly as
many of the patients had large tumours: the mean tumour
diameter was 10.6 cm and the largest tumour resected had a
diameter of 19 cm.
The overall prognosis for patients resected for HCCs arising
in non-eirrhotic livers is not clear because in most series there is
a low percentage of non-cirrhotic patients, who are rarely
individualised in the survival curves. Iwatsuki and Starzl26
reported a 5-year survival of 25% in 55 patients who
underwent resection for an HCC in non-eirrhotic liver. Adson
reported a 35% S-year survival among 45 non-eirrhotic
patients." Better results were reported by Ringe et al.,' namely
45% at 5 years, while agasue et al." reported 81% survival at
4 years in a series of 17 patients. Some authors compared
results for resection of HCCs in cirrhotic and non-eirrhotic
livers: agasue et al." reported 4-year survivals of 34.0% and
81.2%, and Ringe et al.3 reported 18.1% and 45.0%, respectively.
More recently Bismuth et al." reported on 68 resections for
HCCs in non-eirrhotic livers. The livers appeared normal at
laparotomy in all cases, but in 13 cases (19%) there were minor
histological abnormalities, such as steatosis or portal fibrosis.
The mean diameter of the tumours was 8.8 cm. Operative
mortality and morbidity were 2.9% and 19.0%, respectively.
The disease-free survival at 1, 3, 5 and 10 years was 69%, 43%,
33% and 19%, respectively. These authors concluded that
ORIGINAL ARTICLES
Fig. 2. a - H&E section showing HCC (arrows) arising in a non-cirrhotic liver, with a portal tract showing mild increase in fibrosis only
(magnification X 2.5). b - Immunohistochemical stain demonstrating strong positivity of hlmour for AFP (magnification X 2.5). c - Activated
endothelial cells in hlmour stain with anti-CD34, while si~usoidal cells in surrounding liver are CD34-negative (magnification X 2.5).
d - Staining with polyclonal CEA outlines the tumour canalicular network (magnification X 10). e - Immunostaining with CK19 shows mild
ductular proliferation in the fibrous tissue at the edge ofa tumour (magnification X 2.5). f - Staining with OV-6 monoclonal antibody shows
prominent bile ductular proliferation to the right ofa tumour (magnification X 10).
survival rates were better after resection of HCCs in patients
with non-cirrhotic livers than in those with cirrhotic livers." The
improved prognosis for patients operated on for HCCs in non-
cirrhotic livers compared with those operated on for HCCs in
cirrhotic livers may be accounted for by the fact that resection
in patients with cirrhosis is associated with a higher mortality
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rate related to the surgical procedure." The disease-free survival
of our patients, most of whom had tumours in non-cirrhotic
livers, was 85%, 75%, and 62% at 1, 2 and 3 years, respectively.
The major long-term problem in our patients, as in all reported




Liver transplantation for HCC remains a controversial issue,
particularly for HCC in a non-cirrhotic liver. We very rarely do
transplants for HCC at OUI institution. Most patients seen by us
have chronic HBV infection and extensive hepatic infiltration
by HCC. There is a high risk of recurrence of both conditions in
the transplanted liver, and the long-term survival is dismal. We
feel that transplantation for malignant disease is not justified in
the face of a shortage of donor organs, and where patients with
non-malignant and non-recurring liver disease are dying while
on the waiting list for transplantation. No liver transplants
have been performed for known HCC in Cape Town since the
establishment of a liver transplantation programme in 1988.
However, a small incidental HCC was found in the liver
explant of one patient transplanted at our institution for
cryptogenic cirrhosis. He remains well with no evidence of
tumour recurrence 7 years after transplantation.
Histopathological examination of the resected specimens
confirmed the rarity of fibrolamellar carcinoma (FLC) in South
Africa. In this study, we found only one case of FLC, in a
24-year-old white man. Diagnosis of FLC is nevertheless
important as this histological subtype has been felt to have a
better prognosis, with resectability rates of 47 - 75% and an
overall survival at 5 years of 25 - 63%.29 However, the belief that
there is improved prognosis with PLC has recently been
questioned.30 Fibrolamellar tumours are generally advanced at
the time of presentation;'" indeed the tumour in our patient
showed evidence of vascular invasion and breaching of the
capsule on histology. Most HCCs examined showed a
trabecular pattern of growth. The tumours were well to
moderately differentiated; we did not use a grading system for
tumours in this study because of lack of correlation with
clinical behaviour and because of tumour heterogeneity, with
several grades often found in the same tumour.3I
Immunostains dearly demonstrated AFP in the cytoplasm,
while canaliculi, often grossly distorted, could be shown with a
polyclonal CEA stain, which cross-reacts with biliary
glycoprotein.n-34 Immunoreactivity of capillaries in HCC was
clearly demonstrated using anti-eD34 for activated endothelial
cells.l;.J6
Because staining of sinusoids in cirrhotic liver is virtually
negative with anti-eD34, this antibody may be a good marker
for distinguishing well-differentiated HCC from non-neoplastic
regenerative nodules in a cirrhotic liver.37;l8 These
immunocytochemical markers are particularly useful in the
diagnosis of difficult cases of malignant hepatic tumours where
the histogenesis was in doubt.31.39
When human liver cancer arises in cirrhotic livers, the
increased incidence of HCC is probably related to increased
liver cell turnover.'5 In the non-neoplastic areas of cirrhotic liver
in patients with HCC, cells have been identified that resemble
the 'oval cells' (stem cells) and 'transitional cells' seen in rats
during experimental hepatocarcinogenesis. These cells are
thought to be possible progenitors of mature hepatocytes.-IO In a
study of 14 HCC resection specimens from China, Hsia
et al." observed the proliferation of a new population of
epithelial cells in actively regenerating nodules and in liver
tissue surrounding the cancers. These 'oval-like' cells stained
strongly positive for CK19 and with OV-6 monoclonal antibody
against rat oval cells. Oval cells and transitional types of cells
appeared to be the principal producers of AFP in the
regenerating liver.4! In a subsequent study of 26 HCC resection
specimens, oval cells and transitional cells were shown to
contain HBsAg and/or hepatitis B core antigen by
immunohistochemistry." In this study of 14 surgical specimens,
irnmunostaining with CK19 and OV-6 demonstrated mild
nonspecific ductular proliferation in non-neoplastic livers of
cirrhotic patients, but no AFP production. 0 proliferation of
stem cells was observed in liver adjacent to HCC. Presumably
the oval cell proliferation observed by others is related to the
increased cell turnover in livers with end-stage cirrhosis.43
CONCLUSIONS
Surgical resection for cure is appropriate for a small group of
carefully selected patients with HCC. Extensive resections for
large tumours are well tolerated in young patients with non-
cirrhotic livers. The main long-term problem in these patients
remains recurrence of HCC. Liver transplantation for HCC is
not a realistic option in South Africa. The vast majority of HCC
patients present with advanced disease and the prognosis is
dismal.
The authors wish to thank Dr Sedick Isaacs for calculating the
survival curve, Mrs Heather McCleod and Mrs Rochelle Barnard
for expert technical assistance with the immunohistochemistry, and
Professor Peter Cruse and Dr Wendy Spearrnan for critical review
of the manuscript.
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YEAR-ROUND HOUSEDUST MITE
LEVELS ON THE HIGHVELD
A Cadman, R Prescott, P C Potter
Objective. To determine the levels of the allergen DerPl,
attnbutable to the house-dust mite (HDM) Dermatophagoides
pteronyssinus.
Design. A four-season study conducted during 1994/95,
sampling mattresses and carpets in the main bedrooms of
suburban homes.
Setting. Thirty randomly selected homes in the Edenvale area,
occupied by both black and white families living under
similar socio-economic conditions in comparable
environments.
Results, All homes tested positive for the allergen, and in 20"10
HDM levels exceeded levels recognised as 'safe' in terms of
respiratory allergy, i.e. 2 JIg/g of dust. Once mites were
established in a home, they remained for months thereafter.
The considerable seasonal variation recorded in HDM levels
could not readily be explained.
Conclusicm. The HDM is extremely sensitive to minimal
variations in microclimate. Its year-round presence is of
concern on the Highveld. Infestation levels below 2 JIg/g of
dust, until recently considered the critical point for
sensitisation, may be Significant triggers of symptoms.
5 AIr Med J1998; 88: 1580-1582.
The house-dust mite (HDM), Dermatophagoides pteronyssinus,
forms part of the natural ecosystem of the human habitat. This
small creature, approximately 300 JlI1l. in length, feeds on
human skin scales discarded by the body. The optimal
environment for the mite is the bed, in and on the mattress,
pillows and bedlinen. It is also found on carpets and soft
furnishings. The mite faeces contain a protein that is known to
be a major cause of respiratory allergy, particularly in humid
and warm environments such as exist in coastal areas of
KwaZulu- atal.'" Although the hot, dry conditions of the
Highveld might appear to preclude HDM, the earlier wor'( of
Ordrnan' showed that HDMs were indeed present in Highveld
homes, although frequently in lower numbers than at the coast.
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